If approved, Relday will be the first subcutaneous antipsychotic product that allows for once-monthly dosing. In July 2011, we licensed from DURECT exclusive global rights to develop and commercialize this proprietary formulation which utilizes DURECT’s SABER® depot technology. We believe that Relday will offer an improved pharmacokinetic profile, significant reduction in injection volume and a simplified dosing regimen due to DURECT’s SABER controlled-release formulation technology.
Relday™ is a trademark of Zogenix, Inc.
SABER® is a trademark of DURECT.